28 October 20925 - Tens of thousands of Australians living with chronic kidney disease will soon have access to more cheaper medicines on the Pharmaceutical Benefits Scheme.

Empagliflozin (Jardiance) will be expanded for the treatment of chronic kidney disease, a long-term health condition where kidney function gradually declines. Without treatment, it can progress to end-stage kidney disease, requiring dialysis or transplant.

Read Minister for Health press release